Table 2.
Risk and Burden of Newly Diagnosed T2DM in the COVID-19 Group Compared with the Control Group
| Variable | Total | COVID-19+ | COVID-19− | P value |
|---|---|---|---|---|
| Total no. of subjects | 1,392,720 | 348,180 | 1,044,540 | |
| Newly diagnosed T2DM | 33,339 | 10,668 | 22,671 | |
| Follow-up duration, person-yr | 1,455,356 | 361,223 | 1,094,133 | |
| Incidence rate, /100 person-yr | 2.29 (2.27–2.32)b | 2.95 (2.90–3.01)b | 2.07 (2.05–2.10)b | |
| HR | 1.42 (1.39–1.46)b | 1 (reference) | <0.001 | |
| Adjusted HRa | 1.30 (1.27–1.33)b | <0.001 |
T2DM, type 2 diabetes mellitus; COVID-19, coronavirus disease 2019; COVID-19+, COVID-19 exposure group; COVID-19−, COVID-19 non-exposure control group; HR, hazard ratio.
a
Adjusted for the presence of comorbidities (hypertension and dyslipidemia);
b
Numbers in parentheses indicate 95% confidence intervals.